Patent ID: 9320723
Filing Date: 2016-04-26
CPC Classification: A61K,A61P,C12N,Y10S

Claim Text:
1. A method of treating thyroid eye disease consisting of: administering to a patient having thyroid eye disease one or more DP1 antagonists in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space, wherein said administering is carried out by injecting the one or more DP1 antagonists into the retro-ocular space or applying a composition containing the one or more DP1 antagonists onto a surface of the patient's eye, wherein the DP1 antagonist is from the group consisting of laropiprant, 2-[(1R)-9-(4-chlorobenzyl)-8-((R)-methylsulfinyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid, and 2-[(1R)-9-(4-chlorobenzyl)-8-((S)-methylsulfinyl)-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid.